Richard Silver to Scleroderma, Systemic
This is a "connection" page, showing publications Richard Silver has written about Scleroderma, Systemic.
Connection Strength
16.238
-
Critical Role of LMCD1 in Promoting Profibrotic Characteristics of Lung Myofibroblasts in Experimental and Scleroderma-Associated Lung Fibrosis. Arthritis Rheumatol. 2023 03; 75(3):438-448.
Score: 0.638
-
Systemic sclerosis: Choosing patients wisely when treating interstitial lung disease. Nat Rev Rheumatol. 2017 08; 13(8):455-456.
Score: 0.434
-
Management of Systemic-Sclerosis-Associated Interstitial Lung Disease. Rheum Dis Clin North Am. 2015 Aug; 41(3):439-57.
Score: 0.375
-
Update on scleroderma-associated interstitial lung disease. Curr Opin Rheumatol. 2014 Nov; 26(6):630-6.
Score: 0.360
-
Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr. 2014 Mar-Apr; 38(2):163-8.
Score: 0.344
-
Editorial: molecular insights into systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2014 Mar; 66(3):485-7.
Score: 0.344
-
Systemic sclerosis and the heart. Rheum Dis Clin North Am. 2014 Feb; 40(1):87-102.
Score: 0.337
-
Factors associated with oral hygiene practices among adults with systemic sclerosis. Int J Dent Hyg. 2014 Aug; 12(3):180-6.
Score: 0.335
-
Factors associated with gingival inflammation among adults with systemic sclerosis. Int J Dent Hyg. 2014 Feb; 12(1):55-61.
Score: 0.324
-
Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol. 2012 Nov; 24(6):642-8.
Score: 0.314
-
Effect of orofacial exercises on oral aperture in adults with systemic sclerosis. Disabil Rehabil. 2012; 34(1):84-9.
Score: 0.291
-
Paraspinal tumoral calcinosis in a child with systemic sclerosis/myositis overlap. Pediatr Radiol. 2011 Sep; 41(9):1216-8.
Score: 0.286
-
Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr; 29(2 Suppl 65):S26-32.
Score: 0.283
-
Biomarkers of scleroderma lung disease: recent progress. Curr Rheumatol Rep. 2011 Feb; 13(1):44-50.
Score: 0.278
-
Gastroesophageal reflux incites interstitial lung disease in systemic sclerosis: clinical, radiologic, histopathologic, and treatment evidence. Semin Arthritis Rheum. 2010 Dec; 40(3):241-9.
Score: 0.265
-
Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. Semin Arthritis Rheum. 2010 Aug; 40(1):73-88.
Score: 0.241
-
Endothelin and scleroderma lung disease. Rheumatology (Oxford). 2008 Oct; 47 Suppl 5:v25-6.
Score: 0.236
-
Outcome measures in the lung. Rheumatology (Oxford). 2008 Oct; 47 Suppl 5:v48-50.
Score: 0.236
-
Histopathology and bronchoalveolar lavage. Rheumatology (Oxford). 2008 Oct; 47 Suppl 5:v62-4.
Score: 0.236
-
Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol. 2008 Oct; 295(4):L603-11.
Score: 0.234
-
Captive of art, not disease. Paul Klee and his illness, scleroderma. Pharos Alpha Omega Alpha Honor Med Soc. 2008; 71(1):16-24.
Score: 0.224
-
Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. Arthritis Rheum. 2007 Oct; 56(10):3468-77.
Score: 0.221
-
Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum. 2007 Jul; 56(7):2432-42.
Score: 0.217
-
Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol. 2006 Feb; 33(2):263-8.
Score: 0.197
-
New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol. 2005 Nov; 17(6):737-45.
Score: 0.193
-
Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Ann Rheum Dis. 2005 Sep; 64(9):1387.
Score: 0.191
-
Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study. Curr Rheumatol Rep. 2005 Apr; 7(2):135-41.
Score: 0.185
-
Correlates of depression, including overall and gastrointestinal functional status, among patients with systemic sclerosis. J Rheumatol. 2005 Jan; 32(1):51-7.
Score: 0.182
-
Thrombin-mediated cellular events in pulmonary fibrosis associated with systemic sclerosis (scleroderma). Clin Exp Rheumatol. 2004 Jan-Feb; 22(3 Suppl 33):S38-46.
Score: 0.170
-
Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol. 2003 Jun; 30(6):1238-43.
Score: 0.163
-
Assessment of lung involvement. Clin Exp Rheumatol. 2003; 21(3 Suppl 29):S19-23.
Score: 0.159
-
Cytochrome P2 polymorphisms and susceptibility to scleroderma: comment on the article by Povey et al. Arthritis Rheum. 2001 Nov; 44(11):2705-6.
Score: 0.146
-
Hospital admissions, length of stay, charges, and in-hospital death among patients with systemic sclerosis. J Rheumatol. 2001 Sep; 28(9):2031-7.
Score: 0.145
-
Systemic sclerosis: environmental and occupational risk factors. Curr Opin Rheumatol. 2000 Nov; 12(6):520-6.
Score: 0.137
-
Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest. 2000 Oct; 118(4):1077-82.
Score: 0.136
-
Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020 03; 8(3):304-320.
Score: 0.130
-
HLA and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. Proc Natl Acad Sci U S A. 2020 01 07; 117(1):552-562.
Score: 0.129
-
Assessment and management of scleroderma lung disease. Curr Opin Rheumatol. 1999 Nov; 11(6):508-13.
Score: 0.127
-
Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis Rheumatol. 2019 12; 71(12):2059-2067.
Score: 0.127
-
Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Clin Exp Rheumatol. 2019 Jul-Aug; 37 Suppl 119(4):115-124.
Score: 0.126
-
Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis. Arthritis Care Res (Hoboken). 2019 03; 71(3):435-447.
Score: 0.121
-
Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. J Rheumatol. 2019 02; 46(2):176-183.
Score: 0.118
-
Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. Arthritis Rheumatol. 2018 10; 70(10):1654-1660.
Score: 0.117
-
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med. 2018 01 04; 378(1):35-47.
Score: 0.112
-
Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. PLoS One. 2018; 13(1):e0189498.
Score: 0.112
-
Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. Medicine (Baltimore). 2017 Dec; 96(51):e8980.
Score: 0.112
-
There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scand J Rheumatol. 2018 Jan; 47(1):62-70.
Score: 0.110
-
Symptomatic spinal calcinosis in systemic sclerosis (scleroderma). Arthritis Rheum. 1997 Oct; 40(10):1892-5.
Score: 0.110
-
Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2017 May; 14(5):682-689.
Score: 0.107
-
Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum. 1997 Apr; 40(4):743-51.
Score: 0.107
-
Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. Clin Exp Rheumatol. 2017 Sep-Oct; 35 Suppl 106(4):106-113.
Score: 0.104
-
Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017 Aug; 76(8):1327-1339.
Score: 0.104
-
Scleroderma. Clinical problems. The lungs. Rheum Dis Clin North Am. 1996 Nov; 22(4):825-40.
Score: 0.103
-
Paul Klee and scleroderma. Bull Rheum Dis. 1996 Oct; 45(6):4-6.
Score: 0.103
-
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.102
-
Systemic Sclerosis and Perceptions of Quality in Primary Care. Am J Med Sci. 2016 05; 351(5):447-51.
Score: 0.099
-
Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. Arthritis Res Ther. 2016 Jan 20; 18:20.
Score: 0.098
-
Genetics of systemic sclerosis: recent advances. Curr Opin Rheumatol. 2015 Nov; 27(6):521-9.
Score: 0.097
-
Scleroderma: diagnosis and treatment, Circa 1995. Bull Rheum Dis. 1995 Oct; 44(6):2-5.
Score: 0.096
-
Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol. 1995 Oct; 22(10):1876-83.
Score: 0.096
-
Systemic sclerosis (scleroderma). Clinical management of its major complications. Rheum Dis Clin North Am. 1995 Feb; 21(1):203-16.
Score: 0.092
-
Interstitial lung disease of systemic sclerosis. Int Rev Immunol. 1995; 12(2-4):281-91.
Score: 0.091
-
Antinuclear antibody-negative systemic sclerosis. Semin Arthritis Rheum. 2015 Jun; 44(6):680-6.
Score: 0.091
-
Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. 2014 Jul; 66(7):1909-19.
Score: 0.088
-
Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol. 2014 Jun; 67(6):706-14.
Score: 0.087
-
Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease. Curr Rheumatol Rep. 2014 Apr; 16(4):411.
Score: 0.087
-
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken). 2014 Mar; 66(3):489-95.
Score: 0.086
-
Bleomycin delivery by osmotic minipump: similarity to human scleroderma interstitial lung disease. Am J Physiol Lung Cell Mol Physiol. 2014 Apr 15; 306(8):L736-48.
Score: 0.086
-
Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis. Am J Hum Genet. 2014 Jan 02; 94(1):47-61.
Score: 0.085
-
Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative. Clin Exp Rheumatol. 2014 Nov-Dec; 32(6 Suppl 86):S-21-7.
Score: 0.085
-
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013 Nov; 72(11):1747-55.
Score: 0.084
-
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov; 65(11):2737-47.
Score: 0.084
-
Failure of the circulatory system limits exercise performance in patients with systemic sclerosis. Am J Med. 1993 Oct; 95(4):413-8.
Score: 0.084
-
Differential regulation of cell functions by CSD peptide subdomains. Respir Res. 2013 Sep 08; 14:90.
Score: 0.083
-
Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993 May; 20(5):838-44.
Score: 0.081
-
Lung disease in systemic sclerosis (scleroderma). Baillieres Clin Rheumatol. 1993 Feb; 7(1):79-97.
Score: 0.080
-
Growth and characterization of fibroblasts obtained from bronchoalveolar lavage of patients with scleroderma. J Rheumatol. 1992 Nov; 19(11):1716-23.
Score: 0.078
-
Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care Res (Hoboken). 2012 Mar; 64(3):351-7.
Score: 0.075
-
Clinical aspects of localized and systemic scleroderma. Curr Opin Rheumatol. 1991 Dec; 3(6):973-8.
Score: 0.074
-
Clinical aspects of systemic sclerosis (scleroderma). Ann Rheum Dis. 1991 Nov; 50 Suppl 4:854-61.
Score: 0.073
-
High resolution computed tomography in early scleroderma lung disease. J Rheumatol. 1991 Oct; 18(10):1520-8.
Score: 0.073
-
Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis. J Rheumatol. 2011 Aug; 38(8):1622-30.
Score: 0.071
-
Coagulation and autoimmunity in scleroderma interstitial lung disease. Semin Arthritis Rheum. 2011 Oct; 41(2):212-22.
Score: 0.069
-
Lymphokine activated killer (LAK) cell activity in the peripheral blood lymphocytes of systemic sclerosis (SSc) patients. Clin Exp Rheumatol. 1990 Sep-Oct; 8(5):481-6.
Score: 0.067
-
Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S55-62.
Score: 0.067
-
Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol. 2010 Jul; 37(7):1488-501.
Score: 0.067
-
Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990 May; 88(5):470-6.
Score: 0.066
-
Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. Ann Rheum Dis. 2010 Jun; 69(6):1220-6.
Score: 0.066
-
Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29; 322(13):874-81.
Score: 0.066
-
Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol. 2010 Apr; 176(4):1983-98.
Score: 0.065
-
Lung disease associated with progressive systemic sclerosis. Assessment of interlobar variation by bronchoalveolar lavage and comparison with noninvasive evaluation of disease activity. Am Rev Respir Dis. 1990 Feb; 141(2):301-6.
Score: 0.065
-
Lung involvement in systemic sclerosis. Rheum Dis Clin North Am. 1990 Feb; 16(1):199-216.
Score: 0.065
-
Progressive systemic sclerosis sine scleroderma presenting as pulmonary interstitial fibrosis. Am J Med. 1989 Nov; 87(5):525-7.
Score: 0.064
-
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum. 2009 Nov; 60(11):3455-64.
Score: 0.064
-
A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer? Arthritis Rheum. 1989 Jul; 32(7):817-25.
Score: 0.062
-
Spontaneous production of fibronectin by alveolar macrophages in patients with scleroderma. Arthritis Rheum. 1989 May; 32(5):577-83.
Score: 0.062
-
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009 Apr; 60(4):1102-11.
Score: 0.061
-
Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009 Apr; 36(4):773-80.
Score: 0.061
-
Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol. 2009 Feb; 36(2):330-6.
Score: 0.060
-
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May; 68(5):620-8.
Score: 0.060
-
European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2009 May; 68(5):629-34.
Score: 0.059
-
Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo. Am J Physiol Lung Cell Mol Physiol. 2008 May; 294(5):L843-61.
Score: 0.056
-
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008 Jan 01; 177(1):91-8.
Score: 0.055
-
Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
Score: 0.055
-
Interstitial lung disease in systemic sclerosis. Lung. 2007 Jul-Aug; 185(4):211-20.
Score: 0.054
-
Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007 Jun; 34(6):1277-82.
Score: 0.054
-
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis. Ann Rheum Dis. 2007 Dec; 66(12):1641-7.
Score: 0.054
-
Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
Score: 0.054
-
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
Score: 0.050
-
Interstitial lung disease in scleroderma. Immune complexes in sera and bronchoalveolar lavage fluid. Arthritis Rheum. 1986 Apr; 29(4):525-31.
Score: 0.050
-
Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005 Oct; 32(10):1888-92.
Score: 0.048
-
Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum. 2005 Aug; 52(8):2425-32.
Score: 0.047
-
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. J Rheumatol. 2005 May; 32(5):832-40.
Score: 0.047
-
Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. Arthritis Rheum. 2005 Feb; 52(2):592-600.
Score: 0.046
-
Interstitial lung disease in scleroderma. Analysis by bronchoalveolar lavage. Arthritis Rheum. 1984 Nov; 27(11):1254-62.
Score: 0.045
-
Myofibroblast induction and microvascular alteration in scleroderma lung fibrosis. Clin Exp Rheumatol. 2004 Nov-Dec; 22(6):733-42.
Score: 0.045
-
Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005 Jan; 288(1):L190-201.
Score: 0.045
-
Curcumin-induced apoptosis in scleroderma lung fibroblasts: role of protein kinase cepsilon. Am J Respir Cell Mol Biol. 2004 Jul; 31(1):28-35.
Score: 0.043
-
Ethnic differences in cytotoxic T lymphocyte associated antigen 4 genotype associations with systemic sclerosis. J Rheumatol. 2004 Jan; 31(1):85-7.
Score: 0.043
-
HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. J Rheumatol. 2003 Nov; 30(11):2392-7.
Score: 0.042
-
Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol. 2003 Aug; 163(2):571-81.
Score: 0.041
-
Anti-fibrillin-1 autoantibodies in systemic sclerosis are GM and KM allotype-restricted. Exp Clin Immunogenet. 2001; 18(3):123-9.
Score: 0.035
-
Solvent oriented hobbies and the risk of systemic sclerosis. J Rheumatol. 1999 Nov; 26(11):2369-72.
Score: 0.032
-
Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol. 1999 Jul 15; 163(2):1066-72.
Score: 0.031
-
Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol. 2019 02; 71(2):182-195.
Score: 0.030
-
Is occupational organic solvent exposure a risk factor for scleroderma? Arthritis Rheum. 1998 Jun; 41(6):1111-8.
Score: 0.029
-
M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in vitro and in vivo. Transl Res. 2016 Apr; 170:99-111.
Score: 0.024
-
Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am J Respir Cell Mol Biol. 1994 Apr; 10(4):405-12.
Score: 0.022
-
Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR Am J Roentgenol. 1993 Aug; 161(2):269-72.
Score: 0.021
-
Endothelial GATA-6 deficiency promotes pulmonary arterial hypertension. Am J Pathol. 2013 Jun; 182(6):2391-406.
Score: 0.020
-
Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome. Arthritis Rheum. 1992 Sep; 35(9):1097-105.
Score: 0.019
-
Alterations in tryptophan metabolism in the toxic oil syndrome and in the eosinophilia-myalgia syndrome. J Rheumatol. 1992 Jan; 19(1):69-73.
Score: 0.019
-
Scleroderma following augmentation mammoplasty. Report of a case and review of the literature. Arch Dermatol. 1990 Sep; 126(9):1198-202.
Score: 0.017
-
Familial clustering of scleroderma spectrum disease. Am J Med. 1988 Jun; 84(6):1023-32.
Score: 0.014
-
Dipyridamole decreases platelet-derived growth factor levels in human serum. Arteriosclerosis. 1987 Mar-Apr; 7(2):152-8.
Score: 0.013
-
Anticentromere antibody and immunoglobulin allotypes in scleroderma. Arch Dermatol. 1985 Mar; 121(3):339-44.
Score: 0.012
-
Opposing effects of protein kinase Calpha and protein kinase Cepsilon on collagen expression by human lung fibroblasts are mediated via MEK/ERK and caveolin-1 signaling. J Biol Chem. 2005 Apr 08; 280(14):13879-87.
Score: 0.011
-
Fibronectin distribution in nailfold biopsies of scleroderma (systemic sclerosis) patients. Acta Derm Venereol. 1985; 65(3):185-9.
Score: 0.011
-
Epidermal nuclear immunofluorescence: serological correlations supporting an in vivo reaction. Br J Dermatol. 1985 Jan; 112(1):15-22.
Score: 0.011
-
Immunofluorescence in skin specimens from three different biopsy sites in patients with scleroderma. Clin Exp Rheumatol. 1985 Jan-Mar; 3(1):11-6.
Score: 0.011
-
Association between fluorescent antinuclear antibodies, capillary patterns, and clinical features in scleroderma spectrum disorders. Am J Med. 1984 Nov; 77(5):812-22.
Score: 0.011
-
Immune complexes and antinuclear, antinucleolar, and anticentromere antibodies in scleroderma. J Am Acad Dermatol. 1984 Sep; 11(3):461-7.
Score: 0.011
-
Fasciitis (not scleroderma) following prolonged exposure to an organic solvent (trichloroethylene). J Rheumatol. 1994 Aug; 21(8):1567-70.
Score: 0.006